

Beckman Coulter expands collaboration with Fujirebio for neurodegenerative disease assays

12 March 2024 | News

New assays are being developed for the recently launched Beckman Coulter Dxl 9000 Immunoassay Analyzer

American firm Beckman Coulter Diagnostics, a clinical diagnostics leader, and Japan-based Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, have announced an expansion of their partnership focused on development, manufacturing and clinical adoption of neurodegenerative disease assays.

In 2023, Beckman Coulter and Fujirebio entered into a collaboration agreement focused on new biomarkers aligned with recently approved monoclonal antibody-based Alzheimer's disease therapeutics. These new drugs are proving to be major milestones in slowing down disease progression and improving patients' health.

This announcement extends this research programme and further refines target analytes, including a pTau217 plasma assay being developed by Beckman Coulter and a Beta Amyloid 1-42 plasma assay being developed by Fujirebio.

These new assays are being developed for use on the recently introduced Beckman Coulter Dxl 9000 Immunoassay Analyzer. The Dxl 9000 Analyzer's novel Lumi-Phos PRO Substrate has shown the capability to develop increasingly sensitive and clinically relevant assays.

This agreement leverages Fujirebio's expertise in the development, manufacturing and regulatory registration of its Neurological Reagent Kits and its expansive Neurological Biomarker menu. Fujirebio has developed a full complement of research use only (RUO) blood-based neurodegenerative biomarkers including β -amyloid1-42, β -amyloid1-40, phospho-Tau181, neurofilament light (NfL), ApoE4, Pan-ApoE and phospho-Tau217.